Article Text
Statistics from Altmetric.com
The TRANSCEND trial1 studied a cohort of more than 250 patients with relapsed/refractory non-Hodgkin's lymphoma treated with the chimeric antigen receptor T-cell (CART) product, lisocabtagene maraleucel. This trial enrolled a high number of patients and included a relatively long follow-up (36 months).
Estimating the gain in overall survival (OS) for CART patients versus non-CART controls suffers from the lack of long-term survival information for CART. One advantage of the TRANSCEND trial is the availability of survival results at 36 months; this allows us to reliably determine the survival gain. To carry out this estimation, we kept in mind that the restricted mean survival time (RMST) is recognised to be the best outcome measure for managing long-term survival …
Footnotes
Contributors AM and LB performed the analysis, DM and MC separately did the same analysis, and the results were compared. The four co-authors equally contributed to writing the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; internally peer reviewed.